• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Clinical Data's Vital Scientific N.V. Executes OEM Agreement With Sclavo Diagnostics International S.R.L. To Sell Clinical Chemistry Instrumentation in Europe, the Middle East and Africa

Posted on: Wednesday, 11 April 2007, 03:00 CDT

Clinical Data, Inc. (NASDAQ: CLDA) announced today that Vital Scientific N.V., the European arm of its Vital Diagnostics division, signed an OEM agreement with Sclavo Diagnostics International S.r.l. of Sovicille (Siena), Italy, to sell the Company's line of automated clinical chemistry analyzers in Europe, the Middle East and Africa, and to provide installation and first line support services.

Sakari Boman, Director of Sales and Business Development for Vital Scientific, said, "We are very pleased to reach this multi-year agreement, and we look forward to working closely with Sclavo Diagnostics to more broadly distribute our technology throughout Europe, the Middle East and Africa. This partnership with Sclavo Diagnostics follows clearly our strategy to further strengthen our OEM businesses."

"Sclavo Diagnostics is pleased to bring the Sclavolab product line to our international customers," said Angelo Fracassi, Chairman, D-Group S.P.A. "This technology provides a new level of automation to our customers and extends the value proposition we offer to customers. This agreement allows Sclavo Diagnostics to place Vital Scientific clinical chemistry systems into small-to-medium hospital laboratories and in all private laboratories."

About Vital Diagnostics

Vital Diagnostics is a leading manufacturer and distributor of clinical laboratory instrumentation and reagents for in-vitro diagnostic applications. The company has over 45 years of expertise in the development and production of automated and semi-automated analyzers marketed worldwide under the Vitalab® label. With an established distribution network operating in over 150 countries, Vital Diagnostics has built dedicated and well-trained sales and service organizations adept at providing top-of-the-line equipment, reagents, services and support to its broad range of clients.

About Clinical Data, Inc.

Clinical Data, Inc. is a global biotechnology company unlocking the potential of molecular discovery, from targeted science to better healthcare. Its PGxHealth division focuses on genetic test and biomarker development to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics division provides molecular and pharmacogenomics services to both research and regulated environments. Its Vital Diagnostics division offers in vitro diagnostics solutions for the clinical laboratory. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists and health plans worldwide.

About Sclavo Diagnostics International S.r.l.

Achille Sclavo develops the serum against anthrax in 1904 and founds the "Istituto Sieroterapico e Vaccinogeno Toscano". In 1934, the first diagnostic products are developed and in 1977 the U.S. Food and Drug Administration grants the registration of these products. In 1992, Sclavo Diagnostics commences business, and in 2003 the plant is moved to the new, technologically avant-garde site in Sovicille (province of Siena). On June 1, 2004, Sclavo Diagnostics International S.r.l. becomes a D-Group company.

Sclavo Diagnostics is now active in research, development, production and marketing of in vitro clinical diagnostic reagents kits in Clinical Chemistry, Specific and Urinary Proteins, Serology, Immunology, Bacteriology and Molecular Biology.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s),""feel(s),""believe(s),""will,""may,""anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to statements regarding: our ability to successfully integrate the operations, business, technology and intellectual property obtained in our acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: our ability to achieve the expected synergies and operating efficiencies from all of our acquisitions; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; general economic downturns; and other risks contained in our various SEC reports and filings, including but not limited to our Quarterly Report on Form 10-Q for the quarter ended December 31, 2006, and our subsequent Current Reports on Form 8-K filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Internet Website: www.clda.com

Source: Business Wire

More News in this Category